Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Quality playbook systems preparing for outpatient procedure expansion focus on protocols, outcomes tracking, and staff readiness amid CMS rule changes.

AI and digital health devices should not be viewed as replacements for health care professionals, but as tools that can be ...

Coronary artery disease characterized by vascular calcification poses significant challenges in the field of interventional ...